CLINICAL_TRIALS
trial_result
· 2014-05-16
Clinical Trial Update: BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia [Phase 2]
Summary
Phase 2 trial of BI 2536 infusional treatment in patients over 60 with refractory or relapsed acute myeloid leukemia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Leukemia, Myeloid, Acute | Phase 2 | Status: COMPLETED